不可切除胰腺癌化疗早期CT体成分变化预后价值
本研究回顾性分析105例不可切除胰腺癌患者,在接受一线化疗前及首次随访CT间测量骨骼肌指数等体成分变化。多变量分析显示,校正RECISTv1.1疗效后,ΔSMI仍为总生存的独立预后因素(HR 1.2,95%CI 1.08-1.33,p=0.001),而脂肪组织变化无显著关联。以2.8 cm2/m2/30天为截断值,高ΔSMI组中位生存143天,低ΔSMI组233天(p<0.001)。
要点
- 首次随访CT测量的ΔSMI可独立于RECIST疗效预测不可切除PDAC的总生存。
- ΔSMI截断值2.8 cm2/m2/30天,高骨骼肌丢失速率者生存更差。
- 皮下及内脏脂肪组织指数变化与总生存无显著关联。
局限性
- 回顾性研究设计。
- 样本量有限(105例)。
- 仅纳入不可切除PDAC且接受特定化疗方案者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Skeletal muscle mass is a prognostic factor in pancreatic ductal adenocarcinoma (PDAC). However, it remains unclear whether changes in body composition provide an incremental prognostic value to established risk factors, especially the Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). The aim of this study was to determine the prognostic value of CT-quantified body composition changes in patients with unresectable PDAC starting chemotherapy.
METHODS: We retrospectively evaluated 105 patients with unresectable (locally advanced or metastatic) PDAC treated with FOLFIRINOX (n = 64) or gemcitabine-based (n = 41) first-line chemotherapy within a multicenter prospective trial. Changes (Δ) in skeletal muscle index (SMI), subcutaneous (SATI), and visceral adipose tissue index (VATI) between pre-chemotherapy and first follow-up CT were assessed. Cox regression models and covariate-adjusted survival curves were used to identify predictors of overall survival (OS).
RESULTS: At multivariable analysis, adjusting for RECISTv1.1-response at first follow-up, ΔSMI was prognostic for OS with a hazard ratio (HR) of 1.2 (95% CI: 1.08-1.33, p = 0.001). No significant association with OS was observed for ΔSATI (HR: 1, 95% CI: 0.97-1.04, p = 0.88) and ΔVATI (HR: 1.01, 95% CI: 0.99-1.04, p = 0.33). At an optimal cutoff of 2.8 cm2/m2 per 30 days, the median survival of patients with high versus low ΔSMI was 143 versus 233 days (p < 0.001).
CONCLUSIONS: Patients with a lower rate of skeletal muscle loss at first follow-up demonstrated improved survival for unresectable PDAC, regardless of their RECISTv1.1-category. Assessing ΔSMI at the first follow-up CT may be useful for prognostication, in addition to routine radiological assessment.
KEY POINTS: • In patients with unresectable pancreatic ductal adenocarcinoma, change of skeletal muscle index (ΔSMI) in the early phase of chemotherapy is prognostic for overall survival, even after adjusting for Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) assessment at first follow-up. • Changes in adipose tissue compartments at first follow-up demonstrated no significant association with overall survival. • Integrating ΔSMI into routine radiological assessment may improve prognostic stratification and impact treatment decision-making at the first follow-up.
引用
- Salinas-Miranda E, Deniffel D, Dong X, et al. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol. 2021. PMID: 33934171. doi:10.1007/s00330-021-07899-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。